We are live on ! Find out more
LKFT

Lakefront Biotherapeutics American Depositary Shares

92 hedge funds and large institutions have $1.09B invested in Lakefront Biotherapeutics American Depositary Shares in 2025 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 31 increasing their positions, 29 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

64% more call options, than puts

Call options by funds: $2.33M | Put options by funds: $1.42M

64% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 11

23% more capital invested

Capital invested by funds: $887M → $1.09B (+$201M)

8% more funds holding

Funds holding: 8592 (+7)

7% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 29

0% more funds holding in top 10

Funds holding in top 10: 44 (0)

0.45% less ownership

Funds ownership: 48.1%47.65% (-0.45%)

Holders
92
Holders Change
+7
Holders Change %
+8.24%
% of All Funds
1.21%
Holding in Top 10
4
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.05%
New
18
Increased
31
Reduced
29
Closed
11
Calls
$2.33M
Puts
$1.42M
Net Calls
+$911K
Net Calls Change
-$11.9M
Name Holding Trade Value Shares
Change
Change in
Stake
GS
1
Gilead Sciences
California
$579M
TCM
2
Tang Capital Management
California
$144M +$5.15M +161,083 +4%
MAP
3
Madison Avenue Partners
New York
$76.1M +$10.2M +318,764 +17%
EC
4
EcoR1 Capital
California
$57.7M +$20.2M +630,174 +61%
Ameriprise
5
Ameriprise
Minnesota
$49.1M +$43.6M +1,362,229 +2,490%
PM
6
Prosight Management
Texas
$39.8M -$20M -623,649 -35%
SBH
7
Segall Bryant & Hamill
Illinois
$16.9M -$444K -13,881 -3%
DCM
8
DME Capital Management
New York
$16.7M
Point72 Asset Management
9
Point72 Asset Management
Connecticut
$15.4M +$3.27M +102,369 +30%
Renaissance Technologies
10
Renaissance Technologies
New York
$12.3M -$3.47M -108,500 -23%
Hudson Bay Capital Management
11
Hudson Bay Capital Management
Connecticut
$8.49M -$8.64M -270,000 -52%
BlackRock
12
BlackRock
New York
$8.31M +$441K +13,787 +6%
D.E. Shaw & Co
13
D.E. Shaw & Co
New York
$6.97M +$1.53M +47,984 +31%
UBS Group
14
UBS Group
Switzerland
$5.3M -$2.74M -85,525 -36%
Millennium Management
15
Millennium Management
New York
$5.3M -$1.21M -37,807 -20%
DCM
16
DAFNA Capital Management
California
$4.51M
CSS
17
Cubist Systematic Strategies
Connecticut
$3.62M +$2.95M +92,168 +745%
Voloridge Investment Management
18
Voloridge Investment Management
Florida
$3.03M +$69.4K +2,171 +3%
Goldman Sachs
19
Goldman Sachs
New York
$2.29M +$301K +9,410 +17%
Morgan Stanley
20
Morgan Stanley
New York
$2.22M -$67.2K -2,101 -3%
Fidelity Investments
21
Fidelity Investments
Massachusetts
$1.87M -$47.8M -1,493,017 -97%
JF
22
Jump Financial
Illinois
$1.78M +$850K +26,570 +107%
Primecap Management
23
Primecap Management
California
$1.75M -$2.97M -92,810 -65%
M
24
MATAURO
New York
$1.65M +$1.52M +47,536 New
Barclays
25
Barclays
United Kingdom
$1.35M -$37.3K -1,167 -3%

LKFT Hedge Fund Activity: Q3 2025 in Review

92 of the 7,625 institutional investors tracked by Wall St. Rank reported a position in Lakefront Biotherapeutics American Depositary Shares (LKFT) for Q3 2025, worth a combined $1.09B — up 23% from $887M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new LKFT positions and 11 closed out — a net gain of 7 holders — while 31 added to existing stakes and 29 trimmed.

The largest buyer was Ameriprise, adding an estimated $43.6M. The largest seller was Fidelity Investments, cutting an estimated $47.8M.

  • 92 institutional investors held Lakefront Biotherapeutics American Depositary Shares (LKFT) as of Q3 2025, up from 85 in Q2 2025.
  • Funds reported $1.09B of Lakefront Biotherapeutics American Depositary Shares stock for Q3 2025, up 23% quarter-over-quarter.
  • 18 funds opened new Lakefront Biotherapeutics American Depositary Shares positions in Q3 2025 and 11 closed out, a net change of +7 holders.
  • The largest Lakefront Biotherapeutics American Depositary Shares buyer in Q3 2025 was Ameriprise, an estimated $43.6M added.
  • The largest Lakefront Biotherapeutics American Depositary Shares seller in Q3 2025 was Fidelity Investments, an estimated $47.8M sold.

Based on aggregated 13F filings for Q3 2025.